anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided is a method, computer program product, and system for recommending a patient obtain a second medical opinion (SMO) from a second healthcare provider. A processor may collect a first set of attributes associated with a first healthcare provider, the first healthcare provider having identified a first medical opinion for treating a medical condition of a patient. The processor may identify a plurality of healthcare providers that have treated a similar medical condition for one or more other patients. The processor may compare the first set of attributes to a plurality of attributes related to the plurality of healthcare providers. The processor may identify a second healthcare provider based on analyzing similarities between a second set of attributes related to the second healthcare provider and the first set of attributes. Once identified, the processor may provide a recommendation to the patient to obtain a SMO from the second healthcare provider.
BACKGROUND: Acute incarcerated paraesophageal hernias (PEH) have historically been considered a surgical emergency. Emergent operations have a higher rate of morbidity and mortality compared to elective surgery. Our institution has adopted a strategy of initial conservative management in patients presenting with acute obstruction from an incarcerated PEH who are clinically stable. Patients are given at least 24 h for their symptoms to improve (selective nasogastric decompression). If symptoms resolve, contrast on an upper GI study passes to the small bowel, and liquids are tolerated, patients are discharged with planned interval repair. We sought to characterize the outcomes of this interval surgical strategy for incarcerated PEH.
METHODS: A retrospective chart review was performed to identify patients admitted to a single institution between October 2019 and September 2023 with an incarcerated PEH. Patients taken directly to surgery within 24 h were excluded.
RESULTS: A total of 45 patients admitted with obstruction from an incarcerated PEH were identified. Ten patients (22%) were taken urgently to surgery due to clinical instability and were excluded. Of the remaining 35 patients, 23 (66%) resolved their obstruction with conservative non-operative management and were offered planned interval PEH repair (successful conservative management). In the successful conservative management cohort, there was one unplanned readmission before interval PEH repair. Average time between discharge and repair was 25 days. Complication rates did not differ in those who failed and in those who had a successful conservative management result. The cumulative length of stay for those who succeeded in conservative management (including days for the interval surgery) was equivalent with those who underwent PEH repair during the index admission.
CONCLUSION: A trial of conservative management in clinically stable patients with symptomatic incarcerated PEH appears to be safe and often avoids emergent repair without increasing perioperative complications or total days in the hospital.
FIELD: medicine, stomatology. SUBSTANCE: the suggested innovation deals with either lozenge or powder containing dry dosage of one or several antibiotics and one or several compounds of polyvalent metal. Lozenge or powder should be applied right onto aphthous ulcer to be dissolved in saliva during the period of 5-15 min, thus supplying ulcerous tissue with supratherapeutic dosage of antibiotic. Both preparation and method enable to deliver therapeutically high concentration of the above-mentioned polyvalent metal compound and suspension to aphthous ulcer by, thus, developing protective barrier along the whole ulcerous tissue in mouth cavity. EFFECT: higher efficiency of therapy. 44 cl, 1 ex, 3 tbl
508,288. Medicinal preparations; emulsions. BOERICKE, G. W., and YOUNG, W. W. Dec. 22, 1938, No. 37365. [Class 81 (i)] [Also in Group III] A fat sol is prepared by agitating a fat with ethyl alcohol, mixing with approximately three times their volume of distilled water, expelling all but a small proportion-of the alcohol by heat, and filtering the emulsion. The preferred fat is wool fat, and glucose may be added. Kekuni Nut and lecithin sol may be used. Phosphate, sulphates and calcium carbonate may be added to the sols. The sol, the colloidal particles of which are substantially 1 micron in size, is used as a detoxicant therapeutically, either subcutaneously or intravenously.
The role of extracellular nucleotides as modulators of inflammation and cell stress is well established. One of the main actions of these molecules is mediated by the activation of purinergic receptors (P2) of the plasma membrane. P2 receptors can be classified according to two different structural families: P2X ionotropic ion channel receptors, and P2Y metabotropic G protein-coupled receptors. During inflammation, damaged cells release nucleotides and purinergic signaling occurs along the temporal pattern of the synthesis of pro-inflammatory and pro-resolving mediators by myeloid and lymphoid cells. In macrophages under pro-inflammatory conditions, the expression and activity of cyclooxygenase 2 significantly increases and enhances the circulating levels of prostaglandin E2 (PGE2), which exerts its effects both through specific plasma membrane receptors (EP1-EP4) and by activation of intracellular targets. Here we review the mechanisms involved in the crosstalk between PGE2 and P2Y receptors on macrophages, which is dependent on several isoforms of protein kinase C and protein kinase D1. Due to this crosstalk, a P2Y-dependent increase in calcium is blunted by PGE2 whereas, under these conditions, macrophages exhibit reduced migratory capacity along with enhanced phagocytosis, which contributes to the modulation of the inflammatory response and tissue repair.
PURPOSE:To confirm the safety for all handling prescriptions by outputting the propriety of the prescription whose contents are checked by a check means through an output means. CONSTITUTION:The means of medicines, the dose of each recipe, the number of recipe days, etc., written on a prescription are inputted when the screen of a CRT 43 is switched with push of an input key after input of a patient code. Then a check key is pushed after the input key is pushed when the coincidence is secured between the screen and the contents of the prescription. Here the propriety of the recipe is checked including the relation between the inhibition of compound and the past recipe of the patient in terms of the prescription contents. Then a printer 45 prints out an information on an inappropriate recipe and this information can be sent to a doctor, In case the recipe is appropriate, the contents of prescription are sorted into the medicines to be processed by a fully automatic medicine wrapping machine 1 and others. The latter medicines are registered to a memory 44 and at the same time the printer 45 prints out the contents of prescription. Thus the second check is possible with comparison give between the output information and the prescription.
FIELD: medicine, biotechnology, biochemistry. SUBSTANCE: invention relates to method of preparing proteinases inhibitor from cattle organs. Method involves milling and homogenization of the parent raw, extraction in acid medium, mill cake separation and the following purification of end product by desalting from extract using sodium chloride, precipitation of inert proteins with trichloroacetic acid, cation- exchange chromatography, precipitation with acetone and sterilizing filtration of solution. After separation of mill cake chitosan is added to extract, cleared extract is concentrated by ultrafiltration in hollow fibers with passing limit 5 kDa. Eluate obtained after chromatography purification on carboxymethylcellulose is treated with 1% aqueous phenol, precipitate is removed and the end product is precipitated from supernatant with acetone twice followed by precipitate dissolving in 0.9 M sodium chloride solution up to concentration 0.9-1.1 mg/ml. EFFECT: increased yield, enhanced purity of end product. 5 cl, 2 ex
Healthy participants with normal hepatic function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with hepatic impairment.
Children benefiting from assessment and intervention providing by a healthcare professional (physiotherapist or psychomotor therapist) trained and certified for IBAIP. This care will take place upon discharge from the hospital at the rate of one session per month for 6 months. The sessions will take place in the presence of at least one of the parents and at home. These children will also benefit from standard follow-up (medical follow-up, paramedical or specialized medical support depending on the development and needs).
The non-exposure group is the patients who do not take Dayingpian. Patients in this group take conventional mood stabilizers. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
The study will be comprised of healthy, non-pregnant, non-breastfeeding, reproductive age women with regular, ovulatory cycles who are protected from unintended pregnancy via the concurrent use of non-hormonal methods of contraception. Participants will have a mid-luteal screening visit, which will include: informed consent, history, physical, vitals, and assessment of mid-luteal serum progesterone to confirm ovulatory status. Each participant will be assigned to one of three groups according the size of the leading follicle (12-14mm, 15-17mm, ≥18mm), which will determine the timing of the placement of the ENG/EE CVR. Transvaginal ultrasound (TVUS) will be performed three times per week, starting on day 8 of the menstrual cycle, until the leading follicle is within the assigned group. On that day the CVR will be placed and, including day of placement, there will be 6 daily visits with hormonal assays (progesterone, luteinizing hormone) and TVUS to assess for signs of ovulation. Compliance with CVR placement will be assessed through the measurement of serum ENG. After 7 days, participants will remove the CVR at home. Participants will then have biweekly visits until onset of menses to obtain serum progesterone levels and TVUS to assess for signs of delayed ovulation.
Gastric cancer (GC) is one of the most challenging malignant tumors worldwide, primarily because of its high incidence and mortality rates. Prolyl 4-hydroxylase subunit alpha 3 (P4HA3) has been established as a pivotal factor for facilitating cell proliferation, invasion, and metastasis across multiple human tumors. Nevertheless, the precise role of P4HA3in GC has not been fully elucidated. In this study, we used data from The Cancer Genome Atlas (TCGA) to examine the role of P4HA3 as a potential biomarker for predicting immunotherapy response in patients with GC. Our comprehensive analysis of data from the TCGA, TIMER, and other databases revealed a significant association between elevated P4HA3 expression in GC and adverse prognostic outcomes. Furthermore, we confirmed that P4HA3 expression was strongly correlated with immune infiltrating cells, immune infiltration markers, the tumor mutational burden (TMB), microsatellite instability (MSI), the immune score, the stromal score, and immune checkpoints, thus highlighting P4HA3 as a crucial and dependable therapeutic target within the context of immune-based antitumor strategies. Our findings suggest that P4HA3 may function as an immune-related biomarker in the pathogenesis and treatment of GC, indicating that P4HA3 is a promising prognostic and therapeutic target for this malignancy.
OBJECTIVES: To investigate the clinical and echocardiographic presentation of dogs with persistent atrial standstill (PAS), identify variables measured at first presentation that could predict their survival, and document the progression of the disease after pacing.
MATERIALS AND METHODS: Retrospective study of medical records of dogs diagnosed with PAS at three referral hospitals of the United Kingdom over seven years.
RESULTS: Twenty-six dogs were diagnosed with PAS during the study period. Median age of the population was three years (range: seven months-12.5 years). The most common clinical sign was syncope (14/26). Twenty-four dogs received artificial pacemakers (PM). Major complications after PM implantation were observed in four dogs (four/24). Serial echocardiographic examinations showed that cardiac dimensions of PAS dogs with left atrial or left ventricular dilation at first presentation did not return to reference range after pacing. Further dilation of the cardiac chambers, recurrence of congestive heart failure (CHF), or development of new episodes of CHF were documented in seven, four, and 10 PAS dogs, respectively, despite pacing. Median survival time for cardiac-related deaths after PM implantation was 1512 days (18-3207). Neither CHF nor echocardiographic variables at presentation predicted survival after PM implantation in PAS dogs.
CONCLUSIONS: Persistent atrial standstill (PAS) is an uncommon bradyarrhythmia, occurring in young adult dogs. Affected dogs were often presented with syncope. Whilst syncope resolved, cardiac remodeling persisted after PM implantation. Long-term survival was favorable after PM implantation and was not predicted by congestive status or cardiac chamber size at first presentation.
The present invention relates to the field of molecular vaccinology. Provided is a recombinant multi-component SARS-CoV-2 trimer protein vaccine capable of inducing broad-spectrum neutralization activity. The components of a recombinant protein comprise, but are not limited to, a homotrimer protein which is formed by introducing mutation sites and trimerization auxiliary structures into the extracellular domains (ECD) of spike proteins (S protein) of Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron (BA.1, BA.4/BA.5). The multi-component vaccine comprises the ECD trimer protein of a single component or any combined components of the variants and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immune and cellular immune responses. The multi-component SARS-CoV-2 trimer protein vaccine can be used for preventing infection-related diseases caused by infection of SARS-CoV-2 and the variants thereof.
Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
PROBLEM TO BE SOLVED: To provide a solid-phased carrier in which an indicator molecule is solid-phased stably to a carrier, and a manufacturing method of the solid-phased carrier.SOLUTION: A solid-phased carrier 1 is obtained by solid-phasing an indicator molecule 10 to a carrier 100 via a molecule complex 2. The molecule complex 2 comprises a first molecule 3, a second molecule 4 and a third molecule 5. The first molecule 3 includes a guest molecular structure 31 and a linear structure 32 bound to the guest molecular structure 31. The second molecule 4 includes a cyclodextrin structure 41 and is positioned in the middle of a length direction of the linear structure 32 while passing the linear structure 32 of the first molecule 3 through a hole that the cyclodextrin structure 41 has. The third molecule 5 includes a cucurbituril structure 51 which includes the guest molecular structure 31 within the hole and blocks the cyclodextrin structure 41 of the second molecule 4 from being separated from one terminal side of the linear structure 32 of the first molecule 3. The linear structure 32 of the first molecule 3 is bound to the carrier 100 and the cyclodextrin structure 41 of the second molecule 4 is bound to the indicator molecule 10.
In this research study the investigators want to learn more about an investigational medicine called VE416 in combination with vancomycin (an antibiotic) while undergoing peanut oral immunotherapy. VE416 is a combination of dormant (inactive) bacteria given in a capsule. The bacteria are reactivated once they reach participants intestines and in combination with peanut flour may help to prevent participants from getting sick (upset stomach, breathing problems, and skin problems) when participants come into contact with peanuts.

The investigators are doing this research study to find out if VE416 in combination with vancomycin (an antibiotic) while undergoing peanut oral immunotherapy can help people with peanut allergy. VE416 is a consortium of commensal, or "friendly", dormant (inactive) bacteria given in a capsule. The bacteria are reactivated once they reach participants intestines. The investigators also want to find out if VE416 with peanut oral immunotherapy is safe to take without causing too many side effects.
Cancer-associated anorexia-cachexia is an insidious syndrome that has a major impact on the patient's quality of life, but is also associated with a significant reduction in survival. Unintentional weight loss can predict a poor prognosis in cancer patients which is most likely due to decreased doses of treatment. Despite its clinical importance, it remains a widely underestimated and untreated condition. Considering the scarcity of pharmacological measures, it is necessary to invest in studies that may contribute to the rational and effective treatment of this clinical condition. Mirtazapine has a special therapeutic potential because it is a well-tolerated drug with few adverse effects and with well-known orexigenic action in clinical practice. It has been shown to have side effects of increased appetite and weight gain in cancer subjects with depression and nausea, as well as in non-depressed cancer patients, but there are not, as yet, randomized controlled trials showing its effect on cancer-associated anorexia-cachexia. The objective of this study is to evaluate the effect of mirtazapine as a pharmacological measure in the management of cancer-related anorexia-cachexia in patients in palliative care. A randomized, double-blind clinical trial involving 52 cancer patients with anorexia-cachexia in palliative care will be conducted. Patients will be randomized to receive mirtazapine or megestrol and will be evaluated longitudinally for a period of 8 weeks. After the initial evaluation and randomization, patients will be reassessed after 4 and 8 weeks at an outpatient clinic where they will be evaluated for the following variables: (1) General and demographic characteristics; (2) Usual food intake; (3) Anthropometric evaluation; (4) Presence and degree of symptoms using the Edmonton Symptom Assessment System; (4) Status performance using the Karnofsky performance status; (5) Quality of life using the QLQ-C30 Questionnaire; (6) Depression using the Hospital Anxiety and Depression Scale; (7) Prognosis using the Palliative Prognostic Score; (8) Evaluation of functional capacity using hand grip strength and gait speed; (9) Body composition using electrical bioimpedance and dual energy x-ray absorptiometry; (10) Physical Activity Behaviour using a tri-axial accelerometer. Patients will also be contacted via telephone calls at weeks 1, 2, 3, 5 and 6 for information regarding adverse events and drug compliance. The questioning about the occurrence of adverse events will also be performed at the outpatient clinic. Self-report of ingestion of tablets and counting of tablets on return of packages at the end of the study will be used to determine patient compliance. It is expect that use of mirtazapine can bring benefits increasing appetite and the body weight in cancer patientes in palliative care compared to the use of megestrol.
Norgestimate and ethinyl estradiol was evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, six- (28 day) cycle studies. Two hundred twenty- one patients received Tri-norgestimate and ethinyl estradiol and 234 patients received placebo. Mean age at enrollment for both groups was 28 years. At the end of 6 months, the mean total lesion count changed from 55 to 31 (42% reduction) in patients treated with norgestimate and ethinyl estradiol and from 54 to 38 (27% reduction) in patients similarly treated with placebo. Table 4 summarizes the changes in lesion count for each type of lesion. Based on the investigator’s global assessment conducted at the final visit, patients treated with norgestimate and ethinyl estradiol showed a statistically significant improvement in total lesions compared to those treated with placebo. 

*LOCF: Last Observation Carried Forward
6 to 10 patients aged 18 years and older, diagnosed with MEAK will be enrolled in the study. Patients will be administered a single dose of AUT00201 and matching placebo in a crossover design. The study is comprised of an outpatient screening and procedure orientation followed by approximately 5 days of an inpatient stay at a clinical research unit. After screening/orientation (Visit 1), and baseline assessments (Visit 2), patients will be administered a single dose of 100 mg of AUT00201 or matching placebo the morning of Visit 3. PK assessments will be done at Visits 3, 4, 5, and 6 from predose and up to 27 hours postdose. Visit 4 will be a washout day for patients. At Visit 5 patients will be administered the crossover treatment. At Visit 6 patients will be discharged from the unit. Safety and tolerability assessments will be conducted throughout. PD parameters will also be assessed. Patients will be followed up by telephone 14 days after discharge.